SCHEMBL26025119

SCHEMBL26025119

COCCOc1cc(F)ccc1BO

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ HTT P42858 2/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ HPGD P15428 2/20 0.33
▸ AKT1 P31749 1/20 0.33
▸ HASPIN Q8TF76 1/20 0.33
▸ S1PR4 O95977 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ AR P10275 1/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21731047 0.79 KDM4E (0.39) CYP1A2CYP2C19SMN1; SMN2KDM4EHTT
SCHEMBL27724755 0.78 GAA (0.46) TDP1L3MBTL1CYP1A2CYP2D6CYP2C19
SCHEMBL25974302 0.76 FFAR1 (0.46) TDP1L3MBTL1CYP1A2CYP2D6CYP2C19
SCHEMBL25345554 0.75 ENPP2 (0.39) TDP1L3MBTL1CYP1A2CYP2D6CYP2C19
SCHEMBL29380731 0.75 ALDH1A1 (0.42) TDP1L3MBTL1CYP1A2CYP2D6CYP2C19
SCHEMBL1030557 0.75 ALDH1A1 (0.42) TDP1L3MBTL1CYP1A2CYP2D6CYP2C19
SCHEMBL26024874 0.75 L3MBTL1 (0.38) TDP1L3MBTL1CYP1A2CYP2D6CYP2C19
SCHEMBL23148080 0.74 ALDH1A1 (0.53) L3MBTL1SMN1; SMN2HTTKMT2AHPGD
SCHEMBL14402360 0.74 HPGD (0.47) TDP1L3MBTL1CYP1A2CYP2D6CYP2C19
SCHEMBL26023956 0.73 L3MBTL1 (0.46) TDP1L3MBTL1CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 — — WO disclosed
Send feedback